Texte AlternatifThe acquisition is a significant step on the growth path that Bormioli Pharma has undertaken since December 2017, when it became an independent company owned by Triton Investment Fund. R&G develops, manufactures and sales closure, dosing systems, pipette droppers and tubular glass vials. R&G employs approximately 270 people and operates through 2 plants located in Germany (Schleusingen and Altenfeld).

“This acquisition is part of a wider development plan aimed to make of Bormioli Pharma a truly global and innovative player” – Andrea Lodetti, Bormioli Pharma’s CEO, affirmed – “Through this operation Bormioli Pharma reinforces its presence in the German and Northern European markets, expands its current offering with complementary products and strengthens its manufacturing footprint adding more technological capabilities”.

All rights reserved except agreement written by Emballage Digest or mention of the magazine